SAFETY OF MELOXICAM IN TREATMENT OF JUVENILE ARTHRITIS IN CHILDREN
Abstract
The study estimated the safety of meloxicam in prolonged treatment of children with juvenile arthritis (JA). Clinical data and results of endoscopy of 50 patients with JA were analyzed. All patients were switched from diclofenac to meloxicam by different reasons. An estimation of hepatotoxicity of meloxicam compared to other non-steroidal anti-inflammatory drugs (NSAIDs) — diclofenac and nimesulid, was performed. The results of a study show that treatment with meloxicam decreases a risk of gastrointestinal adverse events in patients with JA. Hepatotoxicity rate of NSAIDs was 7,2%. Patients treated with meloxicam had lowest rate of transaminases increase.
Key words: children, juvenile rheumatoid arthritis, juvenile chronic arthritis, NSAIDs, gastrotoxicity, hepatotoxicity.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(2):113-118)
About the Authors
E.S. ZholobovaRussian Federation
Z.V. Gesheva
Russian Federation
O.Yu. Konopel’ko
Russian Federation
A.V. Meleshkina
Russian Federation
O.S. Rozvadovskaya
Russian Federation
T.N. Sergeeva
Russian Federation
References
1. Жолобова Е.С., Шахбазян И.С., Климанская Е.В. и др. Роль различных факторов в развитии патологии верхних отделов желудочно-кишечного тракта при хронических артритах у детей. Российский педиатрический журнал. 2003; 3: 37–40.
2. Муравьёв Ю.В. Гепатотоксичны ли НПВП? Научно-практическая ревматология. 2002; 4: 36–41.
3. Rostom А., Goldkind L., Laine L. Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients. Clinical Gastroenterology and Hepatology. 2005; 3: 489–498.
4. Ruperto N., Nikishina I., Pachanov E. et al. A Randomized Double-blind clinical trial of two doses of Meloxicam compared with naproxen in children with JRA. Arthr. Rheum. 2005; 52: 563–572.
5. Traversa G., Bianchi C., Da Cas R. et al. Cohort study of hepatotoxicity associated with nimesulide and other nonsteroidal anti-inflammatory drugs. ВМJ. 2003; 327: 18–22.
6. Walker A. M. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1997; 40: 201–208.
7. Алексеева Е.И., Щербаков П.Л., Бзарова Т.М. и др. Лечение гастропатий с применением ингибиторов протонной помпы рабепразола и эзомепразола у детей с ревматическими заболеваниями. Сборник материалов Х конгресса педиатров России «Актуальные проблемы педиатрии» М. 2006. 18 с.
8. Никишина И. П., Комелягина Е. Г. Рациональные принципы применения нестероидных противовоспалительных препаратов в педиатрической практике. Педиатрия. Прил. 3. 2003; 40–44.
9. Муравьёв Ю. В., Осипова Е. В., Алексеева А. В., Дыдыкина И. С. Токсическое повреждение печени диклофенаком натрия. Клин. фармакология и терапия. 2002; 2: 94–96.
10. Merlani G., Fox M., Oehen H. P., Cathomas G. et al. Fatal hepatotoxicity secondary to nimesulide. Eur. J. Clin. Pharmacol. 2001; 57: 321–326.
Review
For citations:
Zholobova E., Gesheva Z., Konopel’ko O., Meleshkina A., Rozvadovskaya O., Sergeeva T. SAFETY OF MELOXICAM IN TREATMENT OF JUVENILE ARTHRITIS IN CHILDREN. Current Pediatrics. 2010;9(2):113-118.
Email this article 
